Sentences with phrase «tumor patients at»

Three - dimensional CT based radiation therapy is performed on all brain tumor patients at ACIC.

Not exact matches

Immune cells modified by CRISPR - Cas9 were inserted into a lung cancer patient at the West China Hospital in Chengdu in the hopes that they'll be able to fight tumors, and 10 people total will receive injections of CRISPR re-engineered cells in order to assess the method's safety.

It will focus its initial clinical sequencing efforts on cancer, teaming up with the Moores Cancer Center at the University of California, San Diego to sequence the genomes of every patient who is treated there, as well as perform a full genome sequence on their tumors.

But a late - stage clinical trial called CheckMate - 026 for the drug failed to meet its primary goal of halting cancer progression in advanced, untreated patients whose tumors consisted of at least 5 % PD - L1.

When Jedd Wolchok, a cancer doctor and immunologist leading a Yervoy trial at Memorial Sloan Kettering, examined a melanoma patient's scan 12 weeks after he'd received his course of treatment, the results were utterly disappointing — just like those of any other metastatic patient in the final throes of the disease: The tumors had gotten bigger, and there were more of them.

So or so, yes, not - only - external healing by faith itself of physical things (e.g., bullet in the head, tumor, spear in stomach, viri) seems, respectivly technically is, impossible, but i am pretty sure that about any patient appreciates when a surgeon is focusing at the tasks at hand particularly during operation regardless of statistics.

Just weeks after he was named chief medical officer at the Roswell Park Cancer Institute, Dr. Boris Kuvshinoff was diagnosed with an inoperable late - stage tumor in the nasal cavity above his mouth and became a patient there.

Finding individual differences in tumors is key to treating the right patient with the right medicine at the right time, researchers say

«Next generation sequencing tools were used to profile patients» tumors,» said Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at UC San Diego Moores Cancer Center.

However, the majority of patients develop treatment - resistant tumors, and only 10 to 15 percent of these patients survive long term, says Ie - Ming Shih, M.D., Ph.D., the Richard W. TeLinde Distinguished Professor in the department of Gynecology and Obstetrics, who led the study with Tian - Li Wang, Ph.D., an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine.

Steven Rosenberg, chief of surgery at NCI, riveted everyone's attention by recounting the varied success of treating patients with tumor - infiltrating lymphocytes and then took a few moments to address audience members about advancing their scientific careers.

In a paper published in the May 5 online issue of The Oncologist, researchers at the University of California, San Diego School of Medicine and Moores Cancer Center detail their experience evaluating 34 patients between December 2012 and June 2013 using a molecular tumor board — a new type of advisory group comprised of multidisciplinary experts, including those in the fields of tumor genetics, basic science and bioinformatics.

«Particularly in such patients with underlying CKD, our modeling results support the integration of renal tumor anatomic features at cross-sectional imaging into decision making for treatment of small renal masses and may be used to provide a patient - centered framework for selection of optimal candidates for ablative therapy,» Kang said.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.

Led by Stella K. Kang, a radiologist with the Department of Radiology at the New York School of Medicine, the study was designed to compare the effectiveness of a treatment algorithm for small renal tumors incorporating the nephrometry score, a renal tumor anatomy scoring system developed by urologists, with the current standard of uniformly recommended partial nephrectomy in patients with mild - to - moderate chronic kidney disease (CKD).

«Understanding tumor microbiology will help us improve our existing chemotherapies treatments for cancer patients, says Danino, a biomedical engineering professor at Columbia Engineering.»

They analyzed patient factors such as age, stage at diagnosis, histologic type, Breslow thickness (a measurement of how deep the tumor is), and ulceration.

«Surgery is the main treatment option for patients with most solid tumors, but recurrence and metastasis remain significant problems,» says study senior author Michael Goldberg, PhD, assistant professor at Dana - Farber and Harvard Medical School.

Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.

«Although radiosurgery has been shown to be an effective post-surgical treatment for metastatic brain tumors, previous studies did not compare patient outcomes from a single hospital over the same period of time,» said N. Scott Litofsky, M.D., chief of the Division of Neurological Surgery at the MU School of Medicine and senior author of the study.

To illustrate that point, they analyzed a series of 95 patients with a confirmed diagnosis of brain tumor at their department.

Doctors might order a CT or MRI scan for a headache or migraine to put patients» minds at ease about fears that a malignant brain tumor, aneurysm, arteriovenous malformation or other issue might be causing their symptoms.

«Most cancer patients are actually at risk of having their tumor spread to multiple sites,» Dr. Massagué notes.

Prostate cancer risk groups are assigned based on the prostate biopsy results, which include the Gleason score (GS)-- an indication of how aggressively the tumor cells may behave — and the prostate specific antigen (PSA) level in the patient's blood at the time of diagnosis.

HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumor samples and discovered that specialized immune cells in brain tumor patients are compromised.

The authors conclude, «Unvalidated guidelines to prevent neuroimaging in patients with headaches may reduce the perceived global economic burden at the expense of medical errors, delayed diagnoses, and inferior outcomes for patients with brain tumor.»

Coley was fascinated by a smattering of curious cancer stories referenced in the medical literature of the era: Patients riddled with inoperable tumors suddenly found themselves cancer - free after contracting erysipelas, another potentially fatal ailment at the time, caused by Streptococcus bacteria and marked by fever and hardened, painful rashes.

Elaine Mardis: In 2013 there were numerous studies [that provide] growing evidence that linking a patient's tumor genotype to a drug or drugs can achieve at least temporary remission.

The team looked at tumor samples taken from 314 patients diagnosed with DCIS.

Studies in cancer patients indicate reduced rates of relapse when patients are pretreated with epigenetic drugs due to its far - reaching capabilities; killing progenitor cells at the site of the tumor, in circulation, or at a distant site.

But toxin - induced infections were unpredictable; the patient at right had 63 injections before his tumor shrank.

In the next phase of the study, researchers will genetically sequence tumor cells from at least 500 patients and follow the course of their disease.

Researchers at the University of Cincinnati (UC) College of Medicine have shown that a new targeted treatment could benefit patients with certain pancreatic tumors by preventing spread of the cancer and protecting their heart from damage — a direct result of the tumor.

«This study gives important new insights into why nearly all melanoma patients fail targeted therapy,» explained Keiran S. Smalley, Ph.D., associate member of the Tumor Biology Program at Moffitt.

They examined the tumors of nearly 300 patients at the CHU de Grenoble.

The investigators looked at 4,278 tumor samples from a tissue repository of patients with GI tract cancers.

«We are looking to optimize the combinations of targeted therapies and the scheduling of those therapies so we can improve tumor shrinkage and minimize potential toxicities for a patient,» said Andrew Aplin, PhD, Associate Director for Basic Research and the Program Leader for Cancer Cell Biology and Signaling (CCBS) in the NCI - designated Sidney Kimmel Cancer Center at Jefferson Health.

Most cancer patients would opt for tumor profiling even if the test revealed that they or their families were at risk for other genetic diseases, according to a Yale Cancer Center study.

«This study opens the door for combination therapy with BRAF inhibitors and autophagy inhibitors, which haven't been explored deeply as a therapeutic option for patients whose tumors are resistant,» said Ravi K. Amaravadi, MD, assistant professor of Medicine in the division of Hematology / Oncology at the Perelman School of Medicine and co-leader of the Cancer Therapeutics Program at Penn Medicine's Abramson Cancer Center.

A global analysis of metabolites and small molecules in urine samples from patients with adrenal cancer has identified four biochemicals that, when measured together, can distinguish malignant from benign adrenal tumors, according to study results presented at the 2015 Annual Clinical Congress of the American College of Surgeons.

«In the clinic, we frequently test myc levels in patients» tumors, for disease prognosis and to predict treatment response,» said Michael Pourdehnad, MD, a clinical oncologist at UCSF with Ruggero's lab and the first author of the study.

«The power of this study is that we looked at genes discovered to be over-expressed in patients» tumors and determined their function in kidney cancer, which has not been done on a large scale before,» he says.

RNA sequencing of both single and clustered CTCs from breast cancer patients identified several genes expressed at elevated levels in CTC clusters, one of which — a protein called plakoglobin — also was overexpressed in the primary tumors of patients with reduced survival.

«It's a very delicate balance,» he adds, «staying just at the edge of the envelope, getting out all the tumor, and only the tumor, leaving the patient with absolutely no loss of function.»

«Despite the identification of circulating tumor cells (CTCs) and cell - free DNA (cfDNA) as biomarkers capable of providing clinically relevant information in cancer patients, at present their identification is not routinely used in clinical practice,» explains Silvia Morbelli, MD, PhD, of the IRCCS San Martino — IST National Cancer Research Institute and University of Genoa in Genoa, Italy.

A team of biomedical engineers at Vanderbilt University headed by Assistant Professor Melissa Skala has developed the technique, which uses fluorescence imaging to monitor the response of three - dimensional chunks of tumors removed from patients and exposed to different anti-cancer drugs.

Fine got federal approval this year to try such a drug screen on one patient whom he describes as «well - connected,» creating an organoid from her cells and adding bits of her tumor to it in hopes of throwing drug after drug at it until one vanquished the organoid's cancer.

Outcomes were excellent irrespective of patient age at diagnosis, tumor size, and tumor grade.

Second, we believe the vaccine may be particularly beneficial for a group of patients with the HLA - A2 type, which suggests that as we move forward, there may be advantages in targeting this population,» said John Yu, MD, vice chair of the Department of Neurosurgery, director of surgical neuro - oncology, medical director of the Brain Tumor Center and neurosurgical director of the Gamma Knife Program at Cedars - Sinai.

To better understand the formation of metastases in pancreatic cancer, Christine Iacobuzio - Donahue, M.D., Ph.D., professor of pathology at Memorial Sloan Kettering Cancer Center, collected tumor samples from eight patients with the most common form of pancreatic cancer (pancreatic ductal adenocarcinoma) immediately after their deaths.